The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped significantly in the last few years, a new survey shows. The YouGov poll, ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

The government’s five‑year experiment could be the first step toward broad public coverage of GLP‑1 drugs. If a new experiment pans out, Medicaid and Medicare could begin covering the costly ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Medicare and Medicaid move toward covering Ozempic and other weight loss drugs - The proposed plan could go into effect as early as next April for those on Medicaid ...

The Trump administration is preparing a five-year pilot program that could allow Medicare and Medicaid to cover expensive GLP ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...